Reliance Industries' subsidiary Strand Life Sciences was granted an Indian patent on July 7, 2026 for an AI-enabled blood test that detects early-stage cancer using cell-free DNA analysis, the company said in a press release carried by ANI. The patented platform combines high-quality genome sequencing, quality control, and machine-learning-based methylation and fragmentomic feature extraction to detect cancer and predict its tissue of origin from a single blood draw. CEO Ramesh Hariharan said the technology aims to make precision cancer screening "more accurate, scalable, and accessible" as India faces over 1.5 million new cancer cases a year. For practitioners, the patent is a concrete example of ML models built on sequencing and epigenetic features being deployed for real clinical screening, not just research.
Amazon Returns to US Bond Market to Fund AI Infrastructure Build